1
Clinical Trials associated with AML1-ETO neoantigen cytotoxic T cells(BGI Shenzhen) / RecruitingEarly Phase 1 A Clinical Study to Evaluate the Safety and Initial Efficacy of Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) in the Treatment of Relapsed or Refractory t(8; 21) AML
1. To evaluate the safety and tolerability of targeted AML1-ETO neoantigen cytotoxic T cells (CTL) in the treatment of relapsed or refractory acute myeloid leukemia .
2. To evaluate the effectiveness of targeted AML1-ETO neoantigen cytotoxic T cells (CTL),by the complete response rate(CRR) and overall survival (OS) followed.
100 Clinical Results associated with AML1-ETO neoantigen cytotoxic T cells(BGI Shenzhen)
100 Translational Medicine associated with AML1-ETO neoantigen cytotoxic T cells(BGI Shenzhen)
100 Patents (Medical) associated with AML1-ETO neoantigen cytotoxic T cells(BGI Shenzhen)
100 Deals associated with AML1-ETO neoantigen cytotoxic T cells(BGI Shenzhen)